BPC-157 appears to accelerate the formation of new microvessels by increasing VEGF expression in fibroblasts and endothelial cells, effectively fast-forwarding the vascularization phase of healing
20 in stock BPC-157 capsules provide a convenient, pre-measured format for laboratory research applications
Duzel et al
nanomolar in cell culture Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to significant differences in metabolism, receptor density, pharmacokinetics, peptide degradation rates, and PepT1 expression patterns
Patients should maintain realistic expectations and continue treatment as prescribed, even if immediate improvements are not apparent, as premature discontinuation can lead to symptom recurrence
The Phase 2 combination trial is planned for H1 2026, with data likely in 2027